New study tracks liver risks of livmarli in kids with rare bile duct diseases
NCT ID NCT07293897
First seen Jan 04, 2026 · Last updated May 13, 2026 · Updated 26 times
Summary
This study looks at how often liver problems happen in children with Alagille syndrome or progressive familial intrahepatic cholestasis who take the drug Livmarli. Researchers will use a Japanese registry of childhood liver disease to track about 50 patients. The goal is to better understand the safety of this treatment in real-world use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALAGILLE SYNDROME (ALGS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Takeda selected site
RECRUITINGTokyo, Tokyo, Japan
Conditions
Explore the condition pages connected to this study.